As talk of drug pricing takes center stage, Amgen slashes Repatha price by nearly 60%
Biotech major Amgen $AMGN has decided to cut its losses, and the price, of its cholesterol drug Repatha in a scramble to claw back its competitive positioning versus Regeneron $REGN and Sanofi $SNY, the team behind its main rival treatment, Praluent.
Following approvals in 2015 the two drugs were pegged to attain blockbuster status for their ability to dramatically lower levels of LDL cholesterol, but instead faced pushback from insurers for their high sticker prices that led to lower adoption than expected, despite later trials that demonstrated the PCSK9 inhibitors also significantly cut the risk of heart attacks and stroke.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.